PDCD1 and cancer: Previous studies have demonstrated that the occurrence of immune-related adverse events (irAEs) is significantly associated with favorable efficacy and prognosis in patients with cancers treated with immune checkpoint inhibitors (ICIs), such as anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T lymphocyte-associated antigen.